| | | A good week for the market generally and biotechs tagged along for the ride. Maybe it was just giddiness from getting past the election on Tuesday, but the second through fifth best stocks seemed all to pop on Wednesday after releasing “exceeds expectations” earnings reports (generally less bad losses). But the real star, in first place with a weekly gain of +194%, was MACK, which owed the stellar return to promising Stage 3 Trial results for its pancreatic cancer drug, announcing that a “New Drug Application” to the FDA was imminent based on those results. This was a case of a big winner not just digging itself out of the previous hole, but is on top of a YTD performance in the black, resulting in MACK now being the number one YTD performer, +214% in the black, eclipsing the long standing holder of that position, CBIO, with a gain of “only” +131%. But the week also produced some remarkable losers as well. ATHX’s -74% in the red performance for the week, wasn’t due to earnings results, but the need to reschedule the “earnings call” with analysts until next week might be a clue. Another tip off? Maybe the headline: Athersys may 'need to cease operations' if debt restructuring fails, reporting that accounts payable are roughly three times cash on hand. ATHX and PLXP had such bad weeks that they also crashed into the YTD bottom 5, ATHX’s “performance” second only to GNCA.
The contest portfolios also had a good week, all but five with a positive return, and a not too shabby median performance of +4.2%. The Top Ten YTD performers also generally showed good form. After slipping off the list in April, this week marks the triumphant return of MOPGCW, the top performer for the week at +39%, and now in second place YTD, (-13%). No surprise, they were the only portfolio with a position in MACK, but also they were one of three portfolios benefitting from TGTX’s good earnings report. DIEGOSAN with an unusually mediocre weekly performance o +0.5% is still top dog, but their YTD performance is just about a wash (-0.1%).
|
Report Time Ranges
|
|
|
From
|
To
|
Recent
|
11/4/2022
|
11/11/2022
|
YTD
|
12/31/2021
|
Index Performance
|
|
Symbol
|
Recent
|
YTD
|
|
^IXIC
|
8.10%
|
-27.62%
|
^NBI
|
3.90%
|
-10.13%
|
^SPSIBI
|
6.09%
|
-24.19%
|
Share Performance
|
Recent
|
YTD
|
Top 5
|
Bottom 5
|
Top 5
|
Bottom 5
|
MACK
|
193.780%
|
ATHX
|
-73.790%
|
MACK
|
214.07%
|
GNCA
|
-99.49%
|
GLYC
|
85.075%
|
CLVS
|
-67.781%
|
CBIO
|
131.22%
|
ATHX
|
-97.11%
|
TGTX
|
59.932%
|
PLXP
|
-39.330%
|
BIOA-B.ST
|
91.99%
|
VLON
|
-95.48%
|
ADAP
|
56.875%
|
OPTN
|
-34.985%
|
FENC
|
86.82%
|
PLXP
|
-95.32%
|
NVTA
|
46.748%
|
AFIB
|
-22.923%
|
PCVX
|
86.72%
|
OTIC
|
-95.21%
|
|
Top 10 Portfolio YTD
|
YTD(Portfolio - SPSIBI)
|
Rec
|
Rec(Port. - SPSIBI)
|
DIEGOSAN
|
-0.09%
|
24.10%
|
0.523%
|
-5.564%
|
MOPGCW
|
-12.83%
|
11.36%
|
39.181%
|
33.094%
|
TECHNETIUM
|
-16.28%
|
7.91%
|
7.924%
|
1.837%
|
GENEGURU
|
-18.16%
|
6.03%
|
10.137%
|
4.050%
|
BRENDAN_49
|
-19.82%
|
4.37%
|
5.853%
|
-0.234%
|
DEW DILIGENCE
|
-21.86%
|
2.32%
|
3.506%
|
-2.581%
|
ROCKY9
|
-24.53%
|
-0.34%
|
3.990%
|
-2.097%
|
A.J. MULLEN
|
-24.81%
|
-0.62%
|
4.861%
|
-1.226%
|
BIOSCIENTISTSA
|
-25.47%
|
-1.28%
|
8.808%
|
2.721%
|
HORSEINALFALFA
|
-26.98%
|
-2.80%
|
-0.006%
|
-6.093%
|
Average and Median Portfolio Performance
|
|
Avg Recent
|
Avg YTD
|
Median Recent
|
Median YTD
|
|
$3,030
|
-36.38%
|
LORBAS
|
$2,524
|
KMASTRA
|
-37.13%
|
5.11%
|
ROCKY9
|
4.220%
|
|
|
